On January 13, 2020 Oncology Venture A/S ("OV" or the "Company") reported that an update of its ongoing clinical development of the PARP inhibitor, 2X-121, will be presented at an upcoming meeting in Boston on January 28-30th (Press release, Oncology Venture, JAN 13, 2020, View Source [SID1234553101]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oncology Venture, a company developing novel cancer treatments along with its best in class companion diagnostic technology, the Drug Response Predictor (DRP), today announces that an update of the company’s ongoing clinical development of its proprietary PARP inhibitor 2X-121 "Titled: A novel drug specific multigene mRNA biomarker for the PARP/Tankyrase inhibitor 2X-121" has been accepted for poster presentation at the upcoming PARP & DDR Inhibitor Summit taking place in Boston on January 28th-30th, gathering VPs, Heads and Directors of Translational Oncology, Target Discovery, and Early Drug Development companies. The poster includes data from the use of a 2X-121 specific DRP biomarker that the company has developed to enable the selection of patients most likely to respond to the drug.
Title: "A novel drug specific multigene mRNA biomarker for the PARP/Tankyrase inhibitor 2X-121"
Session: Poster Session
Date and Time: January 29th at 3:15 pm Eastern Time
Presenter: Dr. Marie Foegh
"We are delighted to be presenting some of our development data in support of our PARP inhibitor 2X-121 at the upcoming PARP & DDR summit meeting as we expect it will enhance the awareness for our unique compound and the DRP platform." said Steve Carchedi, President and Chief Executive Officer of Oncology Venture. "Our novel multi-targeted approach to hitting both PARP and Tankyrase, we believe will provide an improved clinical impact compared to other PARP inhibitors currently approved and/or under development. We look forward to sharing the data set following its presentation later this month".
The company has chosen to publish this announcement now, even though the company is of the opinion that the contents of this announcement does not constitute information which will impact the company’s share price.
However, in the light of the recent events the company finds that expedited access to this information is relevant in order to provide the highest level of transparency for the members of the general public interested in the news flow from the company.